Company Encyclopedia
View More
name
Tandem Diabetes
TNDM.US
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
1.407 T
TNDM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking60/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-109.73%E
    • Profit Margin-20.20%D
    • Gross Margin53.88%B
  • Growth ScoreC
    • Revenue YoY17.87%B
    • Net Profit YoY-60.41%D
    • Total Assets YoY-8.67%E
    • Net Assets YoY-44.06%E
  • Cash ScoreC
    • Cash Flow Margin-495.17%E
    • OCF YoY17.87%B
  • Operating ScoreA
    • Turnover1.1A
  • Debt ScoreE
    • Gearing Ratio84.80%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    17:21 ET Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

    Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care, Inc. shareholders due to allegations of misleading business information. The firm is preparing a class action for investor losses after Tandem's stock fell 19.9% following a voluntary medical device correction announcement. Investors may join the class action without upfront fees. Rosen Law Firm, known for its success in securities class actions, encourages investors to choose experienced counsel.

    prnewswire·
    US
    TNDM
    +3.91%
    prnewswire·
    US
    TNDM
    +3.91%

    Capital Fund Management S.A. Acquires 223,574 Shares of Tandem Diabetes Care, Inc. $TNDM

    Capital Fund Management S.A. increased its holdings in Tandem Diabetes Care, Inc. by 575.4% in Q2, acquiring 223,574 shares. The fund now owns 262,431 shares worth $4.89 million. Other institutional investors also modified their holdings. Tandem Diabetes Care's stock opened at $20.51, with a market cap of $1.39 billion. The company reported Q3 earnings of ($0.31) per share and revenue of $249.25 million. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and a price target of $21.25.

    Market Beat·
    US
    TNDM
    +3.91%
    Market Beat·
    US
    TNDM
    +3.91%

    12:49 ET Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

    Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. due to allegations of misleading business information. Investors who purchased Tandem securities may join a class action for compensation. The investigation follows a voluntary medical device correction announcement by Tandem, which led to a 19.9% stock drop. Rosen Law Firm, known for its success in securities class actions, encourages investors to inquire about joining the class action.

    prnewswire·
    US
    TNDM
    +3.91%
    prnewswire·
    US
    TNDM
    +3.91%

    Tandem Diabetes Care Inc. Files Initial Statement of Beneficial Ownership for Director Sandra Beaver

    Tandem Diabetes Care Inc. has filed an initial statement of beneficial ownership with the SEC, identifying Sandra Beaver as a Director. This filing is accessible via EDGAR, the SEC's system. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    TNDM
    +3.91%
    Reuters·
    US
    TNDM
    +3.91%

    Bernstein Keeps Their Hold Rating on Tandem Diabetes Care (TNDM)

    Bernstein analyst Lee Hambright maintained a Hold rating on Tandem Diabetes Care with a price target of $18.00. Hambright, who covers the Healthcare sector, has an average return of 8.5% and a 70.73% success rate. Tandem Diabetes Care also received a Hold rating from TR's Lila Implantra and a Buy rating from Barclays.

    Tip Ranks·
    US
    TNDM
    +3.91%
    Tip Ranks·
    US
    TNDM
    +3.91%
    © 2025 Longbridge｜Disclaimer